You just read:

Promentis Pharmaceuticals Announces Positive Results for Phase 2A Study of SXC-2023 Targeting Novel Glutamatergic Mechanism and Completion of Enrollment for Phase 2 Trichotillomania Study

News provided by

Promentis Pharmaceuticals, Inc.

Oct 31, 2019, 16:03 ET